Mattias Bernow
CEO
Cellcolabs
Cellcolabs specializes in the industrial-scale, GMP production of high-quality mesenchymal stromal cells (MSCs) for research and clinical applications. By providing these cells, the company aims to enhance the availability and affordability of MSCs, facilitating advancements in treatments for severe and incurable diseases.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$21.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Research and clinical applications of mesenchymal stromal cells (MSCs) are often hindered by limited availability and high costs associated with their production. This scarcity restricts the pace of research and the development of MSC-based therapies for severe and incurable diseases.
Solution
Cellcolabs specializes in the large-scale, GMP-compliant manufacturing of high-quality MSCs to increase their accessibility and affordability. By providing a reliable supply of MSCs, Cellcolabs aims to accelerate research and development in regenerative medicine and facilitate the translation of MSC-based therapies to clinical use. Their production processes are designed to meet the stringent quality requirements for both research-grade and clinical-grade MSCs.
Target Audience
Cellcolabs serves researchers in academia and industry, as well as clinicians and pharmaceutical companies involved in developing and testing MSC-based therapies.
Features
- Industrial-scale production of MSCs to ensure consistent supply
- GMP-compliant manufacturing processes for clinical-grade MSCs
- Stringent quality control testing to ensure cell purity, viability, and potency
- MSCs characterized for key markers and functional properties
- Customizable cell sourcing and expansion protocols to meet specific research needs